Search

Author/Creator Martin, Ross

21. Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) From Dolutegravir (DTG)+F/TAF or DTG+F/Tenofovir Disoproxil Fumarate (TDF) in the Presence of Pre-existing NRTI Resistance. (1st November 2020)

Authors:
Acosta, Rima K.; Willkom, Madeleine; Andreatta, Kristen; Liu, Hui; Martin, Ross; Parvangada, Aiyappa; Martin, Hal; Collins, Sean; White, Kirsten L.
Journal:
Journal of acquired immune deficiency syndromes
Issue:
Volume 85:Number 3(2020)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

22. Three-year study of pre-existing drug resistance substitutions and efficacy of bictegravir/emtricitabine/tenofovir alafenamide in HIV-1 treatment-naive participants. (21st April 2021)

Authors:
Acosta, Rima K; Chen, Grace Q; Chang, Silvia; Martin, Ross; Wang, Xinxin; Huang, Hailin; Brainard, Diana; Collins, Sean E; Martin, Hal; White, Kirsten L
Journal:
Journal of antimicrobial chemotherapy
Issue:
Volume 76:Number 8(2021)
Page Start:
2153
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗